Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa). More information about FYARRO, including full prescribing information and important safety information can be found at www.fyarro.com, with additional information about Aadi available on the corporate website at www.aadibio.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
There are currently no events scheduled.